TheraGenetics Expands Research and Development Team with the Appointment of Two Industry Veterans

CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--TheraGenetics Limited, a personalized medicine diagnostics company that is developing and commercializing a portfolio of pharmacogenetic diagnostic tests to guide and improve the treatment of central nervous system (CNS) disorders, announced today the appointment of two industry veterans to newly created positions: Susan E. Bromley, Ph.D., to Global Head of R&D and Kenneth B. Milne, Ph.D., to UK Director of R&D.